470 likes | 684 Views
Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009 Slide set – six summary data slides and all 40 figures from the report.
E N D
Towards universal access: scaling up priority HIV/AIDS interventions in the health sector Progress report 2009 Slide set – six summary data slides and all 40 figures from the report
Increase in antiretroviral therapy in low- and middle-income countries, adults and children [combined], December 2007–December 2008
Antiretroviral therapy coverage in low- and middle-income countries, adults and children [combined], December 2008
Antiretroviral therapy coverage in low- and middle-income countries, adults (≥15 years), December 2008
Antiretroviral therapy coverage in low- and middle-income countries, children (0–14 years), December 2008
Prevention of mother-to-child transmission coverage in low- and middle-income countries, December 2008
Number of people receiving antiretroviral therapy in low- and middle-income countries, by region, 2002–2008
Fig. 2.2. Reported number of health facilities providing HIV testing and counselling services in low- and middle-income countries with comparable data, by region, 2007 and 2008
Fig. 2.3. Percentage of women with HIV testing and counselling and percentage of women with secondary or higher education, district comprehensive assessment districts in Burkina Faso, Haiti and Zambia, 2008
Fig. 2.4. Percentage of women and men receiving an HIV test and test results in the 12 months preceding the survey in countries with repeat population surveys, 2003–2008
Fig. 2.5. Percentage of women and men (≥15 years) who had ever received an HIV test and test results, South Africa, 2002, 2005 and 2008
Fig. 3.1. Situation analysis of harm reduction interventions in the Middle East and North Africa at baseline, 2008
Fig. 4.1. Number of people receiving antiretroviral therapy in low- and middle-income countries, by region, 2002–2008
Fig. 4.2. Measuring attrition from antiretroviral therapy programmes
Fig. 4.3. Retention on antiretroviral therapy at 12 months after initiation of treatment in 61 low- and middle-income countries by region, 2008
Fig. 4.4. 12-month retention of people receiving antiretroviral therapy in selected treatment sites, Papua New Guinea, 2008
Fig. 4.5. Trends in retention on antiretroviral therapy in low- and middle-income countries by region, 2008
Fig. 4.6. Trends over time in the median CD4 count at baseline count of 36 715 adults starting antiretroviral therapy between 2001 and 2006
Fig. 4.7. Antiretroviral therapy coverage and all-cause mortality in South Africa, 2003–2006
Fig. 4.8. Countries implementing at least one element of the WHO Global Strategy for the Prevention and Assessment of HIV Drug Resistance and locations of HIV drug resistance testing laboratories, February 2009
Fig. 4.9. Main first-line antiretroviral regimens used among 2.4 million adults in 36 low- and middle-income countries, December 2008
Fig. 4.10. Main second-line antiretroviral regimens used among adults (n=51 135) in 36 low- and middle-income countries, December 2008
Fig. 4.11. First-line regimens used among children (n=177 064) in 36 low- and middle-income countries, December 2008
Fig. 4.12. Second-line regimens used among children (n=5997) in 35 low- and middle-income countries, December 2008
Fig. 4.13. Median annual cost (in US dollars) of first-line antiretroviral drug regimens in low-income countries by year, 2004–2008
Fig. 4.14. Median annual cost (in US dollars) of first-line antiretroviral drug regimens in lower-middle-income countries by year, 2004–2008
Fig. 4.15. Median price (in US dollars) of first-line antiretroviral drug regimens in upper-middle-income countries by year, 2004–2008
Fig. 4.16. Estimated HIV prevalence (%) among people newly infected with TB, 2007
Fig. 4.17. Rates of HIV testing among people with TB in countries in sub-Saharan Africa, 2004–2007
Fig. 5.1. Number of low- and middle-income countries with national scale-up plans including population-based targets for preventing mother-to-child transmission and for HIV care and treatment for children, by region, 2008
Fig. 5.2. Percentage of women and men aged 15–49 years with comprehensive knowledgea of HIV in countries with recent population-based surveys (2007–2008)
Fig. 5.3. Reported percentage condom use at last sexual intercourse among women 15–49 years old who had sex in the past year by five-year age groups in selected population-based surveys, 2005–2007
Fig. 5.4. Unmet need for family planning among married women 15–49 years old (%) in countries with a generalized epidemic, 2006–2008
Fig. 5.5. Percentage of pregnant women who received an HIV test in low- and middle-income countries by region, 2004–2008a
Fig. 5.6. Percentage of pregnant women who received an HIV test in Malawi, 2004–2008
Fig. 5.7. Percentage of pregnant women with HIV receiving antiretrovirals for preventing mother-to-child transmission of HIV in low- and middle-income countries by region, 2004–2008
Fig. 5.8. Percentage of pregnant women living with HIV who received antiretrovirals to prevent mother-to-child transmission of HIV in Côte d’Ivoire, 2005–2008
Fig. 5.9. Percentage of pregnant women living with HIV receiving antiretrovirals to prevent the mother-to-child transmission of HIV in 20 countries with the highest HIV disease burden among pregnant women (in descending order), 2008
Fig. 5.10. Coverage of antiretrovirals to prevent the mother-to-child transmission of HIV, 2008
Fig. 5.11. Percentage distribution of various antiretroviral regimens provided to pregnant women in low- and medium-income countries in 2007 and 2008, based on available data
Fig. 5.12. Contribution of the 20 countries with the largest numbers of women needing antiretrovirals for preventing the mother-to-child transmission of HIV to the global gap to reach 80% of those in need, 2008
Fig. 5.13. Coverage of antiretroviral prophylaxis among infants born to mothers living with HIV in low- and middle-income countries by region, 2008
Fig. 5.14. Percentage of pregnant women living with HIV and infants born to them who received antiretrovirals for preventing mother-to-child transmission, 2004–2008
Fig. 5.15. Average age of infants at their first HIV DNA test in Namibia in weeks, 2006–2008
Fig. 5.16. Percentage of children receiving antiretroviral therapy in low- and middle-income countries, 2005–2008